https://orcid.org/0000-0003-1998-548X
References
- Takai K, Nikkuni K, Shibuya H, et al. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki. 2010;51:320–325.
- Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53:57–61.
- Iwaki N, Sato Y, Takata K, et al. Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop. 2013;53:87–93.
- Kawabata H, Kotani S, Matsumura Y, et al. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med. 2013;52:1503–1507.
- Masaki Y, Nakajima A, Iwao H, et al. Japanese variant of multicentric Castleman's disease associated with serositis and thrombocytopenia-a report of two cases: is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop. 2013;53:79–85.
- Tedesco S, Postacchini L, Manfredi L, et al. Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy – a case report. Exp Hematol Oncol. 2015;4:3.
- Konishi Y, Takahashi S, Nishi K, et al. Successful treatment of TAFRO syndrome, a variant of multicentric Castleman's disease, with cyclosporine A: possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med. 2015;236:289–295.
- Fujimoto S, Sakai T, Kawabata H, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94:975–983.
- Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:686–692.
- Masaki Y, Kawabata H, Takai K, et al. Japanese TAFRO Syndrome Research Team. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111:155–158.
- Kawashima M, Usui T, Okada H, et al. TAFRO syndrome: 2 cases and review of the literature. Mod Rheumatol. 2017;27:1093–1097.
- Watanabe R, Fujii H, Kamogawa Y, et al. Chronic lupus peritonitis is characterized by the ascites with a large content of interleukin-6. Tohoku J Exp Med. 2015;235:289–294.
- Riché F, Gayat E, Collet C, et al. Local and systemic innate immune response to secondary human peritonitis. Crit Care. 2013;17:R201
- Pérez-Ruiz M, Ros J, Morales-Ruiz M, et al. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology. 1999;29:1057–1063.
- Sakai K, Maeda T, Kuriyama A, et al. TAFRO syndrome successfully treated with tocilizumab: a case report and systematic review. Mod Rheumatol. 2018;28:564–569.
- Tatekawa S, Umemura K, Fukuyama R, et al. Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep. 2015;3:472–478.
- Nagai T, Maemori M, Ando S, et al. A case of TAFRO syndrome that was refractory to tocilizumab and successfully treated with rituximab. Jpn J Clin Hematol. 2015;56:62.
- Kondo H, Sato Y, Asano G, et al. A case of muticentric Castleman disease (MCD)/TAFRO syndrome that required intensive medical care. J Jap Soc Lymphoretic Tissue Res. 2015;55:115.
- Ozawa T, Kosugi S, Kito M, et al. Efficacy of rituximab for TAFRO syndrome, a variant type of multicentric Castleman’ s disease (in Japanese). Rinsho Ketsueki. 2014;55:350–355.
- Hiramatsu S, Ohmura K, Tsuji H, et al. Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Meneki Gakkai Kaishi. 2016;39:64–71.
- Jain P, Verstovsek S, Loghavi S, et al. Durable remission with rituximab in a patient with an unusual variant of Castleman’s disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015;90:1091–1092.
- Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford). 2005;44:176–182.
- Monach PA, Tomasson G, Specks U, et al. Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2011;63:3988–3997.